牛牛AI助理已提取核心訊息
CRISPR Therapeutics, a leading gene editing company, has announced a registered direct offering of 3,916,082 common shares. The shares are offered at an issue price of $71.50 each, with the Nasdaq Global Market listing under the symbol 'CRSP.' The offering is expected to close on or about February 27, 2024, with T+9 settlement. CRISPR Therapeutics intends to use the net proceeds for general corporate purposes, including research and clinical development, manufacturing infrastructure, and working capital. The offering is made pursuant to a prospectus supplement filed with the SEC and is subject to customary closing conditions.
CRISPR Therapeutics, a leading gene editing company, has announced a registered direct offering of 3,916,082 common shares. The shares are offered at an issue price of $71.50 each, with the Nasdaq Global Market listing under the symbol 'CRSP.' The offering is expected to close on or about February 27, 2024, with T+9 settlement. CRISPR Therapeutics intends to use the net proceeds for general corporate purposes, including research and clinical development, manufacturing infrastructure, and working capital. The offering is made pursuant to a prospectus supplement filed with the SEC and is subject to customary closing conditions.
領先的基因編輯公司CRISPR Therapeutics宣佈註冊直接發行3,916,082股普通股。這些股票的發行價格爲每股71.50美元，在納斯達克全球市場上市，股票代碼爲 “CRSP”。此次發行預計將於2024年2月27日左右結束，並以T+9結算。CRISPR Therapeutics打算將淨收益用於一般公司用途，包括研究和臨床開發、製造基礎設施和營運資金。此次發行是根據向美國證券交易委員會提交的招股說明書補充文件進行的，並受慣例成交條件的約束。
領先的基因編輯公司CRISPR Therapeutics宣佈註冊直接發行3,916,082股普通股。這些股票的發行價格爲每股71.50美元，在納斯達克全球市場上市，股票代碼爲 “CRSP”。此次發行預計將於2024年2月27日左右結束，並以T+9結算。CRISPR Therapeutics打算將淨收益用於一般公司用途，包括研究和臨床開發、製造基礎設施和營運資金。此次發行是根據向美國證券交易委員會提交的招股說明書補充文件進行的，並受慣例成交條件的約束。
有用
沒用